Item 1.01 Entry into a Material Definitive Agreement.

Effective March 18, 2008, the Company and Progenitor Cell Therapy, LLC ("PCT") amended their existing note purchase agreement to accelerate the date for repayment of the outstanding principal, plus interest, by PCT to June 26, 2008 and to acknowledge that no additional moneys will be lent under the agreement beyond the $1 million previously advanced by the Company. In return, the Company agreed to relax certain restrictive covenants and exclusivity provisions.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.